Alcyone Lifesciences

About:

Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain.

Website: http://www.alcyonels.com

Top Investors: Harbor Light Capital Partners, Edgar Jannotta

Description:

Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain. It addresses the unmet needs in the treatment of chronic neuropathological conditions. For many neurologic conditions, there are identified molecular targets, but the blood-brain barrier prevents drugs from addressing those targets from reaching diseased brain regions in a controlled and targeted manner. In addition, there is a fundamental need for control and precision in molecular therapy to the CNS. The company is transforming disease-modifying therapies for rare and orphan disorders through Advanced Precision Delivery Platforms.

Total Funding Amount:

$15.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Ayer, Massachusetts, United States

Founded Date:

2010-01-01

Contact Email:

pjanand(AT)alcyonels.com

Founders:

Adam Fleisher, PJ Anand

Number of Employees:

11-50

Last Funding Date:

2018-01-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai